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ABSTRACT The impact of bacterial species on outcome in bloodstream infections
(BSI) is incompletely understood. We evaluated the impact of bacterial species on
BSI mortality, with adjustment for patient, bacterial, and treatment factors. From
2002 to 2015, all adult inpatients with monomicrobial BSI caused by Staphylococcus
aureus or Gram-negative bacteria at Duke University Medical Center were prospec-
tively enrolled. Kaplan-Meier curves and multivariable Cox regression with propensity
score models were used to examine species-specific bacterial BSI mortality. Of the
2,659 enrolled patients, 999 (38%) were infected with S. aureus, and 1,660 (62%)
were infected with Gram-negative bacteria. Among patients with Gram-negative BSI,
Enterobacteriaceae (81% [1,343/1,660]) were most commonly isolated, followed by
non-lactose-fermenting Gram-negative bacteria (16% [262/1,660]). Of the 999 S. au-
reus BSI isolates, 507 (51%) were methicillin resistant. Of the 1,660 Gram-negative BSI
isolates, 500 (30%) were multidrug resistant. The unadjusted time-to-mortality among
patients with Gram-negative BSI was shorter than that of patients with S. aureus BSI
(P  0.003), due to increased mortality in patients with non-lactose-fermenting Gram-
negative BSI generally (P  0.0001) and Pseudomonas aeruginosa BSI (n  158) in partic-
ular (P  0.0001). After adjustment for patient demographics, medical comorbidities,
bacterial antibiotic resistance, timing of appropriate antibiotic therapy, and source con-
trol in patients with line-associated BSI, P. aeruginosa BSI remained significantly associ-
ated with increased mortality (hazard ratio  1.435; 95% confidence interval  1.043 to
1.933; P  0.02). P. aeruginosa BSI was associated with increased mortality relative to S.
aureus or other Gram-negative BSI. This effect persisted after adjustment for patient,
bacterial, and treatment factors.
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Bacterial bloodstream infections (BSI) are a leading cause of morbidity and mortalityin contemporary medical practice (1–3). The determinants of poor outcome in
patients with BSI are among the most intensely investigated areas of infectious diseases.
Although the intrinsic characteristics of bacterial species are thought to influence
clinical outcomes, there is surprisingly little clinical data to support this impression.
Several studies have shown that patients with Pseudomonas aeruginosa BSI experi-
enced increased crude mortality relative to BSI caused by other bacterial species (4–9).
However, these studies were unable to discriminate how much of this clinical outcome,
if any, was attributable to the intrinsic virulence of P. aeruginosa rather than patient or
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treatment factors. Thus, the impact of the infecting bacterial pathogen on species-
specific differences in patient outcomes of BSI mortality is not clear. This question is of
increasing importance since several therapeutic agents designed to treat or prevent a
single bacterial species, including P. aeruginosa, are under development (10, 11). In this
study, we evaluated relationships between BSI outcomes and infection etiology. We
used a prospectively ascertained cohort of 2,659 hospitalized patients with BSI over a
13-year period from a single center to address the hypothesis that P. aeruginosa BSI will
be associated with a significantly higher in-hospital mortality relative to other bacterial
causes of BSI after adjusting for patient demographics, medical comorbidities, bacterial
antibiotic resistance, and treatment factors.
RESULTS
Epidemiology of bacterial BSI. There were 2,659 adult inpatients with monomi-
crobial S. aureus or Gram-negative BSI identified from 1/2002 to 7/2015. Of these 2,659
patients, 999 (38%) had S. aureus BSI and 1,660 (62%) had Gram-negative BSI. There
were significant demographic differences between the two BSI cohorts (Table 1).
Relative to patients with Gram-negative BSI, patients with S. aureus BSI were younger
(mean 57.7 versus 61.1 years; P  0.0001), more often black (38% versus 29%; P 
0.0001), and more likely to have diabetes mellitus (42% versus 34%; P 0.0001), require
hemodialysis (21% versus 10%; P  0.0001), and have a community-acquired infection
(75% versus 69%; P  0.002). Patients with Gram-negative BSI were more likely to have
had a solid organ or hematopoietic transplant (14% versus 8%; P  0.0001) and a
history of a neoplasm (38% versus 21%; P  0.0001). There were also major differences
in the BSI source. Patients with S. aureus BSI, relative to patients with Gram-negative BSI,
more often had line-associated (26% versus 11%) or skin/soft tissue infections (16%
versus 6%) and less often had a urinary tract infection/pyelonephritis (1% versus 31%)
or biliary tract infection (1% versus 6%; P  0.0001). Patient characteristics among
those with Gram-negative BSI, stratified by bacterial group (e.g., Enterobacteriaceae,
non-lactose fermenters, etc.), are listed in Table S1 in the supplemental material.
There were also significant differences between patients with P. aeruginosa BSI and
non-P. aeruginosa BSI (Table 2). Patients with P. aeruginosa BSI, relative to those with
non-P. aeruginosa BSI, were more often white (77% versus 63%; P  0.001) and more
often had used glucocorticoids in the past 30 days (37% versus 23%; P  0.001), a
history of neoplasm (41% versus 31%; P  0.02) or transplant (25% versus 11%; P 
0.0001), hospital-acquired infections (51% versus 27%; P  0.0001), and higher total
APACHE-II score (mean 16.3 versus 14.4; P  0.0003) and chronic health APACHE-II
score (mean 4.2 versus 3.6; P  0.0003). Patients with P. aeruginosa BSI less often were
hemodialysis dependent (8% versus 14%; P  0.03). There were also significant
differences in the source of BSI, since patients with P. aeruginosa BSI, relative to those
with non-P. aeruginosa BSI, were more likely to have a pneumonia source (25% versus
8%) and less likely to have a line (9% versus 17%) or skin/soft tissue source (6% versus
10%; P  0.0001).
Antimicrobial resistance patterns. Of the 999 S. aureus BSI isolates, 507 (51%) were
methicillin-resistant S. aureus. Of the 1,660 Gram-negative BSI isolates, 500 were MDR
isolates (30%). Both Enterobacteriaceae and non-lactose-fermenting Gram-negative
bacteria exhibited species-specific differences in MDR prevalence (Table 3). Among the
Enterobacteriaceae, the MDR phenotype was most common among Citrobacter freundii
(64% [18/28]), followed by Providencia stuartii (57% [4/7]) and Escherichia coli (45%
[259/577]). Among non-lactose-fermenting Gram-negative bacteria, several species,
including Achromobacter species (3/3), Alcaligenes species (3/3), and Chryseobacterium
species (2/2), exhibited a 100% MDR phenotype. Of note, there were no Enterobacte-
riaceae PDR isolates, though four PDR isolates (2% [4/262]) from the non-lactose-
fermenting Gram-negative bacteria group were isolated. In P. aeruginosa, the MDR
phenotype was present in 28% (45/158) of isolates, and the XDR phenotype was
present in 15% (23/158) of the isolates. Figure S1 in the supplemental material shows
data on MDR trends for BSI isolates of S. aureus, Enterobacteriaceae, and P. aeruginosa.
Thaden et al. Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e02671-16 aac.asm.org 2
Mortality. Kaplan-Meier curves were generated based on all-cause in-hospital
mortality from the date of the index positive blood culture. Of note, Gram-negative BSI
was associated with shorter time to mortality relative to S. aureus BSI (P  0.003) (Fig.
1A). To further determine which group of Gram-negative bacteria was responsible for
this observed difference in mortality, patients with Gram-negative BSI were divided into
those with Enterobacteriaceae versus non-lactose-fermenting Gram-negative BSI, that
together account for 97% of all Gram-negative BSI in this cohort. Time to mortality in
patients with non-lactose-fermenting Gram-negative BSI was substantially decreased
relative to patients with Enterobacteriaceae or S. aureus BSI (P  0.0001) (Fig. 1B). There
was no significant decrease in time to mortality for patients with Enterobacteriaceae BSI
relative to S. aureus (BSI) (P  0.08). Further stratification of patients with non-lactose-
fermenting Gram-negative BSI into P. aeruginosa and other non-lactose-fermenting
Gram-negative BSI illustrated that P. aeruginosa BSI was associated with a shorter time
to mortality than either the S. aureus or other non-lactose-fermenting Gram-negative
BSI (P 0.0001) (Fig. 1C). Patients with non-P. aeruginosa Gram-negative BSI, relative to
those with S. aureus BSI, also had decreased time to mortality (P  0.03). Of note, these
findings did not differ when all instances of bacterial BSI were included for each patient
(i.e., each bacterial BSI event from patients with multiple such events over the study
period were included).
TABLE 1 Demographics of patients with S. aureus and Gram-negative bloodstream
infections at Duke University Medical Center from 2002 to 2015
Parameter
No. (%) of patients
PaS. aureus (n  999)
Gram negative
(n  1,660)
Mean age (yrs) 57.7 61.1 <0.0001
Race/ethnicity
White 597 (60) 1,105 (67) <0.0001
Black 377 (38) 474 (29)
Hispanic 3 (1) 10 (1)
Native American 9 (1) 12 (1)
Asian 4 (1) 23 (1)
Other/unknown 9 (1) 36 (2)
Female 446 (45) 752 (45) 0.75
Medical history
Recent glucocorticoid use 222 (22) 409 (25) 0.16
Neoplasm 210 (21) 639 (38) <0.0001
Diabetes mellitus 418 (42) 568 (34) <0.0001
Transplant 84 (8) 226 (14) <0.0001
Surgery in past 30 days 272 (27) 432 (26) 0.50
Hemodialysis dependence 214 (21) 160 (10) <0.0001
Rheumatologic disorder 30 (3) 39 (2) 0.32
Site of acquisition
Community acquired 746 (75) 1,147 (69) 0.002
Hospital acquired 241 (24) 513 (31)
Source of infection
Pneumonia 100 (10) 122 (7) 0.0001
Urine/pyelonephritis 5 (1) 522 (31)
Abscess 38 (4) 80 (5)
Line associated 263 (26) 187 (11)
Skin/soft tissue 164 (16) 95 (6)
Biliary tract 4 (1) 95 (6)
Other 185 (19) 193 (12)
Source not identified 240 (24) 366 (22)
Mean APACHE-II score 15.3 14.8 0.04
Mean chronic APACHE-II score 3.9 3.6 0.31
aStatistically significant values are indicated in boldface.
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In order to better understand the factors contributing to the observed increased
mortality in patients with P. aeruginosa BSI, we developed a multivariable Cox regres-
sion model that adjusts for patient demographics, medical comorbidities, bacterial
antibiotic resistance, source of infection, timing of appropriate antibiotic therapy and
line removal, and the era in which the BSI occurred (Table 4). In this adjusted analysis,
P. aeruginosa BSI was associated with increased mortality (hazard ratio [HR]  1.435;
95% confidence interval [CI]  1.043 to 1.933; P  0.021). Additional factors associated
with increased mortality in patients with S. aureus or Gram-negative BSI include
increased age (HR  1.376; 95% CI  1.286 to 1.475; P  0.0001), increased APACHE-II
chronic health score (HR  1.168; 95% CI  1.101 to 1.244; P  0.0001), 2005-2015 BSI
era (HR  2.581; 95% CI  1.863 to 3.690; P  0.0001), pneumonia source of BSI (HR 
2.264; 95% CI  1.628 to 3.169; P  0.0001; reference BSI source: urine/pyelonephritis),
and an unidentified BSI source (HR  2.073; 95% CI  1.549 to 2.810; P  0.0001;
reference BSI source: urine/pyelonephritis). Factors associated with decreased mortality
included a skin/soft tissue BSI source (HR  0.531; 95% CI  0.322 to 0.847; P  0.010;
reference BSI source: urine/pyelonephritis). Of note, when a Cox regression model was
repeated with patients from only the 2005-2015 BSI era, there was no significant
change from that described above (see Table S2 in the supplemental material).
TABLE 2 Demographics of patients with P. aeruginosa and non-P. aeruginosa bloodstream
infections at Duke University Medical Center from 2002 to 2015, stratified by bacterial
group
Parameter
No. (%) of patients
Pa
P. aeruginosa
(n  158)
Non-P. aeruginosa
(n  2,501)
Mean age (yrs) 61.9 59.7 0.13
Race/ethnicity 0.001
White 121 (77) 1,581 (63)
Black 29 (18) 832 (33)
Hispanic 0 (0) 13 (1)
Native American 0 (0) 21 (1)
Asian 1 (1) 26 (1)
Other/unknown 7 (4) 38 (2)
Female 64 (41) 1,134 (45) 0.25
Medical history
Recent glucocorticoid use 59 (37) 572 (23) 0.001
Neoplasm 64 (41) 785 (31) 0.02
Diabetes mellitus 53 (34) 933 (37) 0.35
Transplant 39 (25) 271 (11) <0.0001
Surgery in past 30 days 48 (30) 656 (26) 0.26
Hemodialysis dependence 13 (8) 361 (14) 0.03
Rheumatologic disorder 6 (4) 63 (3) 0.30
Site of acquisition <0.0001
Community acquired 78 (49) 1,815 (73)
Hospital acquired 80 (51) 674 (27)
Source of infection <0.0001
Pneumonia 39 (25) 192 (8)
Urine/pyelonephritis 30 (19) 488 (20)
Abscess 6 (4) 112 (4)
Line associated 14 (9) 436 (17)
Skin/soft tissue 10 (6) 249 (10)
Biliary tract 4 (3) 95 (4)
Other 21 (13) 357 (14)
Source not identified 34 (22) 572 (23)
Mean total APACHE-II score 16.3 14.4 0.0003
Mean chronic APACHE-II score 4.2 3.6 0.0003
aStatistically significant values are indicated in boldface.
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Given that P. aeruginosa BSI was associated with increased hospital-acquired BSI
relative to non-P. aeruginosa BSI (51% versus 27%; Table 2), we added an additional
covariate, days from hospital admission to BSI, to the adjusted Cox regression model.
This “days to BSI” covariate was associated with a small but statistically significant
shorter time to mortality (HR  1.005; 95% CI  1.002 to 1.008; P  0.001). When the
“days to BSI” covariate was added to the Cox regression model, P. aeruginosa BSI was
no longer associated with shorter time to mortality (HR  1.335; 95% CI  0.969 to
1.803; P  0.067) (see Table S3 in the supplemental material).
DISCUSSION
Understanding species-specific clinical outcomes associated with bacterial BSI is of
critical importance since it can influence our antibiotic therapy, how closely we monitor
patients, and the development of pathogen-specific therapies (10, 11). Gaining insight
into such species-specific outcomes is challenging given that bacterial species vary in
their sources of BSI, target patients with different demographics and medical comor-
bidities, differ in their antimicrobial susceptibility profiles, and produce variable im-
mune responses. Previous studies that have addressed species-specific differences in
BSI mortality have varied widely in size and geography, addressed limited patient
populations, commonly been retrospective in nature, and have not fully accounted for
the important ways that patient demographics, medical comorbidities, antibiotic resis-
tance, and treatment factors influence bacterial BSI outcomes (4–9, 12–21).
TABLE 3 Antimicrobial susceptibility of Gram-negative bloodstream infection isolates at
Duke University Medical Center from 2002 to 2015a
Organism
No. of isolates detected/total no. of isolates
examined (%)
MDR XDR PDR
Enterobacteriaceae 420/1,343 (31) 4/1,343 (1) 0/1,343 (0)
Escherichia coli 259/577 (45) 0/577 (0) 0/577 (0)
Klebsiella pneumoniae 57/307 (19) 2/307 (1) 0/307 (0)
Proteus mirabilis 10/65 (15) 0/65 (0) 0/65 (0)
Serratia marcescens 5/97 (5) 0/97 (0) 0/97 (0)
Klebsiella oxytoca 9/42 (21) 0/42 (0) 0/42 (0)
Enterobacter cloacae 34/106 (32) 2/106 (2) 0/106 (0)
Enterobacter aerogenes 15/43 (34) 0/43 (0) 0/43 (0)
Salmonella species 7/27 (26) 0/27 (0) 0/27 (0)
Citrobacter freundii 18/28 (64) 0/28 (0) 0/28 (0)
Citrobacter koseri 0/9 (0) 0/9 (0) 0/9 (0)
Morganella morganii 1/13 (8) 0/10 (0) 0/13 (0)
Pantoea agglomerans 1/5 (20) 0/5 (0) 0/(0)
Providencia rettgeri 0/2 (0) 0/2 (0) 0/2 (0)
Providencia stuartii 4/7 (57) 0/7 (0) 0/7 (0)
Other Enterobacteriaceae 1/14 (7) 0/14 (0) 0/14 (0)
Non-lactose fermenters 80/262 (31) 46/262 (18) 4/262 (2)
Pseudomonas aeruginosa 45/158 (28) 23/158 (15) 0/158 (0)
Acinetobacter species 5/26 (19) 4/26 (15) 2/26 (8)
Stenotrophomonas maltophilia 8/26 (31) 8/26 (31) 0/26 (0)
Burkholderia species 4/9 (44) 4/9 (44) 1/9 (11)
Ochrobactrum species 5/6 (83) 0/6 (0) 0/6 (0)
Sphingomonas species ND/6 ND/6 ND/6
Achromobacter species 3/3 (100) 2/3 (67) 1/3 (33)
Alcaligenes species 3/3 (100) 1/3 (33) 0/3 (0)
Moraxella species ND/2 ND/2 ND/2
Roseomonas species ND/4 ND/4 ND/4
Brevundimonas species 2/3 (67) 0/3 (0) 0/3 (0)
Bordetella species ND/2 ND/2 ND/2
Chryseobacterium species 2/2 (100) 1/2 (50) 0/2 (0)
Other non-lactose fermenters 5/12 (42) 3/12 (25) 0/12 (0)
aAntimicrobial susceptibility profiles for anaerobes and Pasteurellaceae are not included here since
antimicrobial susceptibility testing for these bacteria are not routinely performed. Abbreviations: MDR,
multidrug resistant; ND, not determined (by the Duke Clinical Microbiology Laboratory); PDR, pandrug
resistant; XDR, extensively drug resistant.
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In this study, we report one of the most comprehensive analyses of species-specific
differences in bacterial BSI mortality to date. First, our cohort is among the largest
reported cohorts of prospectively enrolled patients with bacterial BSI. This large sample
size resulted in sufficient power to detect species-specific differences while correcting
for all relevant other variables. Second, the patient population that was evaluated—all
inpatients with bacterial BSI at a single large medical center from 2002 to 2015—is
broader than prior studies which have generally performed more focused analyses on
specific patient subpopulations (e.g., nosocomially acquired infections, etc.) in a more
narrow time window. Third, and perhaps most important, we performed a comprehen-
sive analysis that adjusts for patient demographics, medical comorbidities, bacterial
antimicrobial resistance, and treatment factors (e.g., appropriate antibiotic therapy and
source control). Taken together, we performed an extensive analysis on a broad cohort
of patients with bacterial BSI in order to better understand the bacterial species
associated increased mortality and the factors that contribute to that mortality.
In the present study, we found that patients with Gram-negative BSI had increased
mortality relative to S. aureus. This stemmed from non-lactose-fermenting Gram-
negative BSI generally, although patients with P. aeruginosa BSI in particular had a
shorter time to mortality relative to other non-lactose-fermenting Gram-negative BSI. In
a multivariable Cox regression model that included patient demographics, patient
FIG 1 Survival analysis of patients with bacterial bloodstream infections (BSI). (A) Survival in patients with
BSI caused by Gram-negative bacteria compared to that caused by S. aureus. (B) Survival in patients with
BSI caused by Enterobacteriaceae, non-lactose-fermenting Gram-negative bacteria, or S. aureus. (C)
Survival in patients with BSI caused by Pseudomonas aeruginosa, other non-lactose-fermenting Gram-
negative bacteria, or S. aureus.
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medical comorbidities (chronic health APACHE-II score), antibacterial resistance, and
treatment factors, P. aeruginosa BSI was associated with increased mortality relative to
non-P. aeruginosa BSI. Interestingly, adjustment for timing of BSI (i.e., days to BSI from
hospital admission) did partially account for the shorter time to mortality associated
with P. aeruginosa BSI, though even with inclusion of this covariate a borderline
association between P. aeruginosa BSI and shorter time to mortality was present (HR 
1.335; P  0.067). Patients with P. aeruginosa BSI, relative to those with non-P.
aeruginosa BSI, more often had hospital-acquired BSI (51% versus 27%). Prior studies
have demonstrated hospital-acquired infections to be associated with increased mor-
tality (22–24). Although the overall effect of adding the “days to BSI” covariate on the
P. aeruginosa BSI hazard ratio was small (Tables 4 and see Table S3 in the supplemental
material), it is certainly possible that patients with hospital-acquired infections may
have additional risks for poor outcome that were not fully accounted for in our
multivariable Cox regression model. For example, patients with hospital-acquired
infections are likely to be more acutely ill at the time of BSI. We did not account for
degree of acute illness in our adjusted model (e.g., APACHE-II acute physiology score)
since measures of acute illness cannot clearly separate the influence of the BSI from
other acute medical issues. In addition, as described below, the chronic health
APACHE-II score is a broad measure of chronic health/immunosuppression and likely
does not fully account for the complexities of a patient’s chronic medical history.
Several studies have demonstrated increased crude mortality in P. aeruginosa BSI
relative to other bacterial infections (6–9, 12), while others have demonstrated in-
TABLE 4Multivariable Cox regression analysis of clinical and bacterial factors influencing
Staphylococcus aureus and Gram-negative bloodstream infection mortality in inpatients at
Duke University Medical Center from 2002 to 2015a
Parameter Hazard ratio 95% CI P
Age 1.376 1.286–1.475 <0.0001
Female gender 1.129 0.936–1.359 0.203
Raceb
Black 1.223 0.991–1.501 0.058
Other 0.804 0.485–1.253 0.366
Pseudomonas aeruginosa BSI 1.435 1.043–1.933 0.021
APACHE-II chronic health score 1.168 1.101–1.244 <0.0001
MDR 1.051 0.869–1.269 0.609
Appropriate antibiotic therapyc 1.435 0.967–2.202 0.085
Days to line removald
1 0.537 0.192–1.305 0.194
2 0.606 0.232–1.424 0.271
3 0.904 0.259–2.468 0.857
No line-associated infection 7.227 0.392–37.881 0.060
BSI era (2005-2015)e 2.581 1.863–3.690 <0.0001
BSI sourcef
Biliary 0.607 0.303–1.105 0.127
Pneumonia 2.264 1.628–3.169 <0.0001
Line 5.411 0.299–26.650 0.103
Skin/soft tissue 0.531 0.322–0.847 0.010
Abscess 0.721 0.387–1.254 0.273
Other 1.035 0.726–1.476 0.850
Source not identified 2.073 1.549–2.810 <0.0001
aAbbreviations: BSI, bloodstream infection; CI, confidence interval; MDR, multidrug resistant. Statistically
significant values are indicated in boldface.
bThe reference group was composed of white patients.
cThis is a time-dependent variable in which “no appropriate antibiotic therapy” is the reference.
dThe reference group is composed of patients with line-associated infections and line removal on day 0.
eThe reference group is composed of BSI from 2002 to 2004.
fThe reference group is BSI from a urine/pyelonephritis source.
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creased crude mortality with A. baumannii (15, 17) or S. aureus infections (19, 20).
However, adjustment for patient, bacterial, and treatment factors is important for
several reasons. First, P. aeruginosa commonly infects those that are chronically ill or
immunosuppressed, and these patients are at high risk of mortality regardless of
bacterial etiology. Second, P. aeruginosa is often associated with high antibiotic resis-
tance, and the associated delay in appropriate therapy can increase mortality. For
example, Ani et al. published a large retrospective study in which the U.S. “nationwide
inpatient sample” database was queried to identify patients who were hospitalized for
“severe sepsis” and noted that crude mortality associated with P. aeruginosa infections
(29.5%) was higher than that of all Gram-negative species and on par with that of S.
aureus infections (30.9%) (12). However, after adjustment for factors such as the
Charlson comorbidity index and the number of organ failures, P. aeruginosa infection
was associated with improved mortality relative to other bacterial species (HR  0.78;
95% CI  0.78 to 0.81). In contrast to Ani et al., we found that the increased mortality
with P. aeruginosa BSI persisted after adjustment for patient demographics, medical
comorbidities, antibiotic resistance, and treatment factors. There are several explana-
tions for this difference. First, the patient population described in Ani et al. consists of
those with ICD-9 codes involving sepsis and is likely a substantially different population
from that described in this work, which is restricted to patients with documented BSI.
Second, Ani et al. conducted a retrospective study that relied on proper ICD-9 coding
from a diverse set of investigators. Only 38.5% of the identified cases of severe sepsis
were associated with an organism, and this missing data makes it difficult to broadly
generalize their findings. Third, Ani et al. adjusted for the “number of organ failures,”
and this may bias the findings since P. aeruginosa likely causes such high mortality in
part through septic shock and subsequent organ compromise.
Several additional smaller studies have addressed P. aeruginosa BSI mortality using
adjusted models. Kang et al. (n  286; 74 patients with P. aeruginosa BSI) and Micek et
al. (n  535; 114 patients with P. aeruginosa BSI) conducted retrospective studies that
examined P. aeruginosa, Enterobacteriaceae, and A. baumannii (Micek et al. only) BSI
mortality, and each study found P. aeruginosa infection to be associated with increased
mortality in adjusted models (6, 21). S. aureus was not included in these analyses,
however. Osmon et al. compared P. aeruginosa and S. aureus BSI outcome (n  314; 49
patients with P. aeruginosa BSI), although the outcome of interest in the adjusted
model was “response to therapy after 48 h” rather than mortality (8). P. aeruginosa was
associated with a lack of response to therapy in this model. No data regarding adjusted
mortality outcome was presented. Finally, Lambert et al. published a large, multina-
tional study of intensive care unit (ICU) patients throughout Europe (n 1,351 with BSI;
357 patients with P. aeruginosa BSI) with P. aeruginosa, A. baumannii, E. coli, or S. aureus
BSI (15). The outcome in Lambert et al. differed from this study in that ICU mortality was
considered rather than in-hospital mortality. No direct statistical comparisons between
bacterial species were presented, though ICU mortality hazard ratios were highest for
A. baumannii (HR  3.3 to 4.4, depending on antimicrobial resistance phenotype)
relative to P. aeruginosa (HR ranging from 3.2 to 4.0), E. coli (HR ranging from 2.7 to 3.6),
or S. aureus (HR ranging from 2.1 to 3.3). However, direct comparison between Lambert
et al. and this study is complicated by the difference in patient populations and
mortality outcome. Lambert et al. considered only patients in the ICU, who were more
acutely ill and immunosuppressed than the patients examined here. Several smaller
studies performed adjusted analyses that examined the impact of bacterial species on
BSI outcomes, although they found no association between P. aeruginosa and increased
mortality (14, 18).
This study has several limitations. First, the data come from a single institution.
However, given that this is one of the largest cohorts of prospectively enrolled patients
with bacterial BSI over a significant time period (2002 to 2015), we believe that these
data makes a significant contribution to our understanding of how bacterial species
influences BSI mortality. Second, there are additional bacterial species of potential
interest that were not included in this study, such as Enterococcus species and
Thaden et al. Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e02671-16 aac.asm.org 8
coagulase-negative staphylococci. We do not routinely collect data from these patients
and so they could not be included. Nevertheless, we feel that the species that were
included, S. aureus and all Gram-negative bacteria, encompass the vast majority of
clinically relevant species that cause bacterial BSI. Third, the covariate that was used to
account for patient medical comorbidities in our adjusted analysis, i.e., the APACHE-II
chronic health score, does not fully address the complex influence of medical comor-
bidities and immunosuppression on BSI outcomes and is a potential source of unknown
confounders. Nevertheless, we believe that the APACHE-II chronic health score is
appropriate in that it allows us to identify patients at high risk of BSI complications
while avoiding the statistical problems that arise when an excessive number of cova-
riates representing individual medical conditions are included in the model. Finally,
information regarding source control could not be obtained in patients with no
identifiable source of BSI. While the inclusion of such patients is a potential source of
bias, we believe that inclusion of this cohort is important as it reflects the complexity
of modern medical practice in which many potential sources (e.g., multiple lines,
urinary catheter, endotracheal tube, etc.) are present, and a single one cannot be
positively identified. In the present study, we found that an unidentified source of BSI
was associated with increased mortality. This has been noted in prior studies as well (1,
25, 26) and may reflect inadequate source control in patients with an unknown focus
of BSI.
In conclusion, we show that the bacterial BSI mortality associated with P. aeruginosa
is higher than that of other Gram-negative bacteria and S. aureus and that this effect
persisted after adjustment for patient demographics, medical comorbidities, bacterial
antibiotic resistance, and treatment factors. Thus, we attribute this increased mortality
to greater P. aeruginosa virulence in BSI relative to other bacterial species. Additional
study is needed to identify the treatment factors that are needed to improve outcomes
in P. aeruginosa BSI.
MATERIALS AND METHODS
Patient clinical data. From 1 January 2002 to 1 July 2015, all adult inpatients with monomicrobial
BSI due to either Staphylococcus aureus or Gram-negative bacteria at Duke University Medical Center
were prospectively evaluated. Patients who met these inclusion criteria and provided written informed
consent (from patient or legally authorized representative) were enrolled. In patients with multiple
hospitalizations with positive blood cultures, only the first such hospitalization was considered. Patients
with neutropenia were excluded from this study. Detailed clinical data, including patient characteristics,
treatment patterns, and in-hospital outcomes were collected on a standardized case report form and
entered into an electronic database. This study had full approval from the Duke Institutional Review
Board.
Determination of bacterial species and antibiotic resistance phenotypes. All bacteria BSI isolates
were speciated by the Duke Clinical Microbiology Laboratory using standard techniques. MIC values were
determined by the Duke Clinical Microbiology Laboratory with the broth dilution technique, as described
previously (27). MIC breakpoint values for each antibiotic were defined according to the most recent
Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibacterial susceptibility profile of
each bacterial isolate, regardless of the year it was isolated, was defined according to the latest CLSI
guidelines. Antimicrobial resistance phenotypes were defined as previously detailed (28). Briefly, the
multidrug-resistant phenotype (MDR) was defined as nonsusceptible to at least one agent in3 relevant
antimicrobial categories. The extensively drug-resistant (XDR) phenotype was defined as susceptibility to
at least one agent in 2 appropriate antimicrobial categories. The pandrug-resistant (PDR) phenotype
was defined as resistance to all agents in all appropriate antimicrobial categories. For S. aureus,
Enterobacteriaceae, P. aeruginosa, and Acinetobacter species, appropriate antimicrobial categories have
been previously defined (28). For the remaining bacterial species (e.g., Stenotrophomonas maltophilia),
appropriate antimicrobial categories were defined as those with defined CLSI MIC breakpoints for the
particular bacterium (29).
Definitions. The primary endpoint of this study was all-cause mortality. Patients were monitored
through hospital discharge. The “route” of infection refers to whether BSI was hospital-acquired or
community-acquired. Hospital-acquired infection was defined as an infection beginning 48 h after
hospital admission (30). All other infections were defined as community-acquired. The “source” of
infection refers to the primary focus of the BSI (e.g., urine/pyelonephritis, line, etc.). The infection source
was defined retrospectively according to review of the medical record by one of the investigators (J.T.T.).
APACHE-II scores were calculated on the day of the index positive blood culture (31). “Appropriate
antibiotic therapy” is defined as receipt of an antibiotic to which the bacteria are susceptible. Appropriate
antibiotic therapy was determined daily from the date of the index positive blood culture (day 0) to
hospital discharge or death. For line-associated infections, “days to line removal” is the number of days
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from the index positive blood culture to removal of the infected line. Both “appropriate antibiotic
therapy” and “days to line removal” were determined retrospectively by review of the medical record by
one of the investigators (J.T.T.). Two BSI “eras” were defined: (i) 2002 to 2004 and (ii) 2005 to 2015. In 2004
our enrollment practices changed in accordance with U.S. federal legislation (45 CFR 164.512), which
allowed the enrollment of patients who died prior to providing informed consent.
Statistical analysis. Baseline characteristics and clinical events are presented as means with standard
deviation for continuous variables and frequencies with proportions for categorical variables. Statistical
comparisons between groups were made with t tests for continuous variables, Fisher exact tests for
categorical variables with 22 comparisons, and Pearson’s chi-square tests for categorical variables
when more than two levels are relevant. Kaplan-Meier survival curves were used to examine in-hospital
mortality among bacterial groups or species, and the log-rank (Mantel-Cox) test was used to compare
survival distributions. Multivariable Cox regression models were fit to calculate a propensity score
(probability) associated with mortality. Covariates included patient demographics (age, gender, and
race/ethnicity), medical comorbidities (APACHE-II chronic health score), bacterial species, bacterial
antibiotic resistance patterns (the presence of the MDR phenotype), BSI era, source of BSI, and treatment
factors (days to appropriate antibiotic therapy, days to line removal for line-associated infections). In one
model (see Table S3 in the supplemental material), the number of days from hospital admission to index
blood culture (i.e., “days to BSI”) was also included as a covariate. These covariates were selected to
broadly encompass the clinical factors known or thought to influence BSI outcome. The APACHE-II
chronic health score covariate was used to describe degree of chronic illness since it captures severe
organ dysfunction/immunosuppression and avoids the statistical problems that arise when multiple
medical comorbidities are treated as separate covariates. The “appropriate antibiotic therapy” covariate
was treated as a time-dependent variable. The “days to BSI” covariate was treated as a continuous
variable. Statistical significance was determined at the P  0.05 level.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.02671-16.
SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.
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